menu search

ASND / Why Ascendis Pharma Stock Is Plunging Today

Why Ascendis Pharma Stock Is Plunging Today
The FDA has identified deficiencies in Ascendis' regulatory filing for the hypoparathyroidism candidate TransCon PTH. With little info on the nature of the deficiencies, investors are moving to the sidelines today. Read More
Posted: Apr 3 2023, 12:28
Author Name: The Motley Fool
Views: 103096

ASND News  

Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
October 26, 2023

Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this tec more_horizontal

Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?

By Zacks Investment Research
September 15, 2023

Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?

Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might h more_horizontal

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript

By Seeking Alpha
September 5, 2023

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Rela more_horizontal

How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%

By Zacks Investment Research
August 10, 2023

How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%

The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has no more_horizontal

Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data

By Proactive Investors
May 1, 2023

Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data

The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's sto more_horizontal

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript

By Seeking Alpha
April 27, 2023

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript. more_horizontal

Ascendis Pharma: Recent FDA Setbacks Present A Buying Opportunity

By Seeking Alpha
April 16, 2023

Ascendis Pharma: Recent FDA Setbacks Present A Buying Opportunity

We are upgrading from a hold to buy rating for ASND following a 35% drop in stock price after FDA deficiency findings in the NDA for TransCon PTH for more_horizontal

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

By Zacks Investment Research
April 12, 2023

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisio more_horizontal


Search within

Pages Search Results: